Igenica Follows Genentech Into Antibody-Linked Cancer Drugs

Xconomy San Francisco — 

Squint a little, and it’s easy to see the first five years of Burlingame, CA-based Igenica Biotherapeutics as a speeded-up version of the evolution of biotech pioneer Genentech.

Igenica’s leadership ranks are studded with Genentech alumni, including its board chair David Goeddel, a pioneer in gene expression research who was the first scientist Genentech hired. Igenica has just started its first clinical trial on an anti-cancer antibody—-following in the footsteps of Genentech, which developed groundbreaking antibody drugs such as Rituxan, a blockbuster treatment for the blood cancer non-Hodgkin’s lymphoma approved in 1997.

Igenica’s first clinical stage drug, IGN523, is an experimental remedy for acute myeloid leukemia (AML), another cancer that affects white blood cells.

“If we’re wildly successful, IGN523 has the potential to be the Rituxan of AML,” says Igenica CEO Mary Haak-Frendscho.

While Haak-Frendscho is shepherding development of the antibodies like IGN523 that Igenica was founded to develop in 2009, she is also managing the company’s “pivot” to antibody-drug conjugates. These are the double-threat anti-cancer drugs that South San Francisco,CA-based Genentech, now a member of the Roche group, was one of the first to market.

Antibody-drug conjugates have two parts: an antibody that selectively binds to cancer cells, and a toxic drug that can kill those cells. The FDA approved Genentech/Roche/Immunogen’s antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) for patients with HER2-positive, late-stage breast cancer in early 2013.

This year, Igenica plans to choose two of its own antibody-drug conjugates to prepare for clinical trials. Haak-Frendscho sees no latecomer’s disadvantage for Igenica in the hot space. Asked how she sells new investors on the company, she casts Igenica like an observant younger child who watched the older kids crash through the barriers first.

“We let the pioneers spend decades beating the path, and we learned the lessons from them,” Haak-Frendscho says. “We’re not wedded to old technologies.”

One of Igenica’s biggest competitors, however, could be Genentech/Roche, which has a stable of new antibody-drug conjugates already in clinical trials.

Igenica’s bid to produce next-generation antibody-drug conjugates is grounded in the do-it-yourself credo it established from its beginnings as a pure-play developer of “naked antibodies”—those not connected to a toxin. As a first step, the company devised its own method to discover novel molecular targets for drugs. The discovery platform, called sTAg, identified a cell surface protein, CD98, that appears at increased levels on the fast-growing abnormal cells seen in acute myeloid leukemia. CD98, which is also found on other types of cancer cells, helps tumor cells absorb lots of amino acids to feed their rapid growth.

Igenica used its own antibody discovery platform, iTAb, to produce IGN523, which blocks CD98’s ability to serve as an amino acid portal into the cell. As it turns out, crippling CD98 also tips the cancer cell toward apoptosis—a programmed process of cell death—and makes the cell more vulnerable to destruction by the natural killer cells of the immune system, Haak-Frendscho says.

About 90 percent of acute myeloid leukemia cells bear high levels of the CD98 protein, she says. “Most patients have the potential to benefit,” Haak-Frendscho says. “We’re not just addressing a small sub-population here.”

Big pharmaceutical companies including Boehringer Ingelheim and Novartis are also testing drug candidates for acute myeloid leukemia that could some day compete with IGN523.

The first trial participant was dosed with IGN523 in March, under a Phase I trial design developed in discussions with the FDA by Igenica’s vice president of clinical development William Ho. He joined the company in 2012 after leading clinical programs for antibodies and antibody-drug conjugates at Genentech. Although the 33-participant trial is geared toward assessing the safety of varied doses of IGN523, it will also give Igenica a peek at its possible efficacy, and may encourage the company to tackle another cancer type, Haak-Frendscho says.

“Success there would drive us into lung cancer,” she says. Specifically the company would like to test IGN523 against squamous cell carcinoma, a common type of non-small cell lung cancer.

But when Igenica chooses a second clinical stage program, its newer antibody-drug conjugate candidates might … Next Page »

Single PageCurrently on Page: 1 2